<DOC>
	<DOCNO>NCT02568605</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) condition accumulation fat liver lead metabolic dysfunction . Currently approve treatment NAFLD . Part metabolic dysfunction may arise change gut microbiota . Prebiotic fibre beneficial effect glucose tolerance , body weight , gut microbiota ; therefore may potential part dietary strategy NAFLD treatment .</brief_summary>
	<brief_title>Prebiotic Fibre Supplementation Gut Microbiota Non-alcoholic Fatty Liver Disease</brief_title>
	<detailed_description>The main objective study assess effect prebiotic fibre supplementation , conjunction diet-induced weight loss , reduction liver fat injury . Primary Objective - determine change hepatic injury ( fibrosis inflammation ) hepatic fat ( percent fat ) 6 month NAFLD patient treat prebiotic placebo weight loss . Secondary Objectives - determine change appetite , body composition , glycemic insulinemic response , quality life prebiotic placebo weight loss , examine mechanism relate prebiotic-induced change gut microbiota lipogenesis .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult subject diagnose NAFLD basis abnormal liver enzyme ( ALT &gt; 1.5x upper limit normal ) ultrasonography Exclusion cause liver disease include viral hepatitis alcoholic liver disease Aspartate aminotransferase alanine aminotransferase â‰¤10x upper limit normal Patients type 2 diabetes treat diet exercise alone metformin Cirrhosis liver ( FibroScan &gt; 17.5 kilopascal FibroTest &gt; 0.8 ) clinical feature cirrhosis . Alcohol consumption &gt; 20g/day ( 2 standard drink ) woman &gt; 30g/d ( 3 drink ) men Alternate ( e.g . TPN ) concomitant etiology abnormal liver enzyme . History decompensated liver disease include ascites , encephalopathy variceal bleed Concomitant use weight loss medication , previous bariatric intestinal surgery Presence active infection , pregnancy lactation Regular use probiotic prebiotic supplement within 3 month prior enrollment Antibiotic use within 3 month prior enrollment Weight loss &gt; 3 kg within precede 3 month enrollment Uncontrolled cardiovascular respiratory disease , active malignancy , chronic infection Use agent vitamin E , omega3 fatty acid medication evidence effect NAFLD ( pioglitazone , Glucagonlike peptide1 analogue , dipeptidyl peptidase IV inhibitor , ursodeoxycholic acid ) Patients type 2 diabetes HbA1c &gt; 9 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Dietary intervention</keyword>
	<keyword>Prebiotic fibre</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Gut microbiota</keyword>
	<keyword>Obesity</keyword>
	<keyword>Liver fat</keyword>
	<keyword>Hepatic fibrosis</keyword>
</DOC>